YAŞA BAĞLI MAKULA DEJENERASYONUNA SEKONDER KOROİDAL NEOVASKÜLARİZASYONDA İNTRAVİTREAL RANİBİZUMAB TEDAVİSİ SONUÇLARIMIZ

Öz

Yaşa bağlı makula dejenerasyonuna YBMD sekonder koroidal neovaskülarizasyonda KNV intravitreal ranibizumab IVR tedavisinin sonuçlarını değerlendirmek. Bu retrospektif çalışmada daha önce hiç tedavi edilmemiş, YBMD’ye sekonder KNV’u olan ve tekrarlayan IVR enjeksiyonları ile tedavi edimiş olan 67 hastanın 74 gözü değerlendirildi. Hastalara ilk 3 ayda aylık ve daha sonra gerekirse enjeksiyon yapıldı. Her enjeksiyondan sonra 1.gün ve 1.ay, üç enjeksiyon tamamlandıktan sonra aylık olarak muayene edildi. Her muayenede düzeltilmiş en iyi görme keskinliği BCVA ve santral foveolar kalınlık CFT kaydedildi. Üç ayda bir fundus floresein anjiografi FFA uygulandı. Lezyonlar klasik, okkült ve fibrovasküler pigment epitel dekolmanı PED olarak sınıflandırıldı. Hastaların yaş ortalaması 72.7± 9.3 yıl idi. Ortalama izlem süresi 10.6± 5,0 4.0-24.0 ay idi. Klasik KNV’li 22 %29.7 , okkult KNV’li 42 %56.8 ve fibrovasküler PED’i olan 10 %13.5 hasta vardı. Ortalama enjeksiyon sayısı 3.12 idi. Ortalama BCVA 1.08±0.47 logMAR’dan 0.97±0.49 logMAR’a arttı p:0.023 . Ortalama CFT, üçüncü ayda 335.0 µm’den 255.1 µm’e azaldı p

Anahtar Kelimeler

• İntravitreal,ranibizumab,YBMD,koroidal neovaskülarizasyon

THE RESULTS OF INTRAVITREAL RANIBIZUMAB TREATMENT FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE RELATED MACULAR DEGENERATION

Abstract

To evaluate the efficacy of intravitreal ranibizumab IVR in the treatment of choroidal neovascularization secondary to age related macular degeneration. In this retrospective study 74 eyes of 67 patients with choroidal neovascularization CNV secondary to AMD who had no treatment earlier and treated with repeated Ranibizumab injections, were evaluated. Patients had monthly injections during first three months and repeated injections were given as needed later on. Visits were performed at the first day and four weeks after each injection and monthly after the completion of three injections. Best corrected visual acuity BCVA and central foveolar thickness CFT were noted in each visit. Flourescein angiography was performed quarterly. Lesions were classified as classic, occult or fibrovascular pigment epithelial detachment PED . Mean age was 72.7± 9.3 years. Mean follow-up was 10.6± 5,0 4.0-24.0 months. Lesions were classified as classic CNV in 22 29.7% , occult CNV in 42 56.8% and fibrovascular PED in 10 13.5% eyes. Average injection number was 3.12. Mean BCVA increased significantly from 1.08±0.47 logMAR to 0.97±0.49 logMAR p:0.023 . Mean CFT decreased from 335.0 µm to 255.1 µm at third month p

Keywords

• Intravitreal,ranibizumab,AMD,choroidal neovascularization

References

1. ) Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two- year results of the ANCHOR study. Ophthalmology ; 116(1): 57-65. ) Yamashiro K, Tomita K, Tsujikawa A, et al. Factors Associated With the Response of Age-Related Macular Degeneration to Intravitreal Ranibizumab Treatment. Am J Ophthalmol 2012; 154(1): 125-36.
2. ) Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008; (1): 116-26
3. ) Bird AC, Bressler NM, Bressler SB, et al.An international classification and grading system for age- related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995; 39(5):367-74.
4. ) Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102(11):1640-2.
5. ) Bressler SB. Defining the Prevalence of AMD and Investigating Racial Differences. Prevalence rates and racial differences in AMD can help guide the development of screening and treatment policies. Retina Today 2007; 5(1):10.
6. ) Thylefors B. A global initiative for the elimination of avoidable blindness. Am J Ophthalmol 1998; 125(1): 3.
7. ) Macular Photocoagulation Study Group. Subfoveal neovascular degeneration. Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991; 109(9):1242-57.
8. ) Barbazetto I, Burdan A ,Bressler NM, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol 2003; 121(9):1253-68.

9. ) Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40(3): 68.
10. ) Rosenfeld PJ, Schwartz SD, Blumenkranz M, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005; 112(6):1048-53.
11. ) Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascular ization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol ; 120(3):338-46. ) Regillo DC, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol ; 145(2):239-48. ) Rosenfeld PJ, Brown DM, Heier JS, et al.(MARINA Study Group).Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14) : 31.
12. ) Wykrota H, Gierek-Lapiṅska A, Trzciakowski K, Gajdzik-Gajdecka U. Ranibizumab for treatment of exudative age-related macular degeneration-own experience. Klin Oczna 2007; 109(10-12):402-9.
13. ) Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophtalmol 2009; (1):43-58.
14. ) Fung AE, Lalwani GA, Rosenfeld PJ, et al.An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4):566-83.
15. ) Brown DM, Kaiser PK, Michels M, et al (ANCHOR Study Group).Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14):1432-44.